KRAS and pancreatic ductal adenocarcinoma: Furthermore, KRAS-TP53 genomic co-alterations are associated with an immune rejection microenvironment, chemotherapy resistance, and poor survival in patients with pancreatic ductal adenocarcinoma [27].